Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
Philip J.M. Brouwer; Mitch Brinkkemper; Pauline Maisonnasse; Nathalie Dereuddre-Bosquet; Marloes Grobben; Mathieu Claireaux; Marlon de Gast; Romain Marlin; Virginie Chesnais; Segolene Diry; Joel D Allen; Yasunori Watanabe; Julia M. Griezen; Gius Kerster; Hannah L Turner; Karlijn van der Straten; Cynthia A. van der Linden; Yoann Aldon; Thibaut Naninck; Ilja Bontjer; Judith A. Burger; Meliawati Poniman; Anna Z Mykytyn; Nisreen M.A. Okba; Edith E. Schermer; Marielle J. van Breemen; Rashmi Ravichandran; Tom G. Caniels; Jelle van Schooten; Nidhal Kahlaoui; Vanessa Contreras; Julien Lemaitre; Catherine Chapon; Raphael Ho Tsong Fang; Julien Villaudy; Kwinten Sliepen; Yme U. van der Velden; Bart Haagmans; Godelieve J. de Bree; Eric Ginoux; Andrew B. Ward; Max Crispin; Neil P King; Sylvie van der Werf; Marit J. van Gils; Roger Le Grand; Rogier W. Sanders.
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-365726
The SARS-CoV-2 pandemic is continuing to disrupt personal lives, global healthcare systems and economies. Hence, there is an urgent need for a vaccine that prevents viral infection, transmission and disease. Here, we present a two-component protein-based nanoparticle vaccine that displays multiple copies of the SARS-CoV-2 spike protein. Immunization studies show that this vaccine induces potent neutralizing antibody responses in mice, rabbits and cynomolgus macaques. The vaccine-induced immunity protected macaques against a high dose challenge, resulting in strongly reduced viral infection and replication in upper and lower airways. These nanoparticles are a promising vaccine candidate to curtail the SARS-CoV-2 pandemic.
Texto completo
Documentos relacionados